Sinovac's novel H1N1 flu vaccine passes evaluation in China

Reuters is reporting on the first novel H1N1 to pass the test of a regulatory body, Sinovac's vaccine in China:

"The experts agreed that Sinovac's H1N1 vaccine is applicable to people from 3 years to 60 years old and the vaccination schedule is a single shot, the company said in a statement.
The company expects to obtain production license for its vaccine within a week.

Sinovac said the result of the experts' evaluation conference will be submitted to China's State Food and Drug Administration (SFDA), on Sept. 1 and is expected to be the primary opinion for SFDA to issue the production license.

Earlier this month, Sinovac, which is the first company worldwide to complete clinical trials for a vaccine to treat strain of H1N1, said a single dose of its H1N1 vaccine is effective and sufficient."